medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2011, Number 4

<< Back Next >>

Acta Ortop Mex 2011; 25 (4)

Joint position statement of the Mexican College of Orthopedics and Traumatology: Prophylaxis for venous thromboembolic disease in high-risk orthopedic surgery

Meza-Reyes GE, Cymet-Ramírez J, Esquivel-Gómez R, Martínez del Campo-Sánchez A, Martínez-Guzmán MAE, Espinosa-Larrañaga F, Majluf-Cruz A, Torres-González R, De la Fuente-Zuno JC, Villalobos-Garduño E, Méndez-Huerta JV, Ibarra-Hirales E, Valles-Figueroa JF, Aguilera-Zepeda JM, Díaz-Borjón E

Language: Spanish
References: 27
Page: 216-222
PDF size: 60.38 Kb.


ABSTRACT

Venous thromboembolic disease (VTED) is a public health problem worldwide. In the United States it causes 2 million annual cases. Its annual incidence is 1-2 cases per 1,000 individuals in the general population. It is a disease frequently associated with life threatening complications and its mortality rate is 1-5% of cases. Due to its high complication rate, its slow recovery, and the need for prolonged disability, it is considered as a high-cost disease. VTED may occur in both surgical and medical patients; the known associated risk factors include prolonged rest, active cancer, congestive heart failure, atrial fibrillation, and stroke, among the major medical conditions. Orthopedic surgery represents the main surgical risk factor for VTED, including mainly hip and knee replacements, as well as polytraumatized patients with severe spinal lesions, and major fractures. VTED may be prevented with the appropriate use of antithrombotics. The participants in this consensus defined thromboprophylaxis as the strategy and actions undertaken to reduce the risk of VTED in patients undergoing high risk orthopedic surgery. The position of the Mexican College of Orthopedics and Traumatology regarding the prevention of VTED in orthopedic surgery is described herein.


REFERENCES

  1. Zhan C, Miller MR: Excess length of stay, charges and mortality attributable to medical injuries during hospitalization. JAMA 2003; 290: 1868-74.

  2. Warwick D: New concepts in orthopaedic thromboprophylaxis. J Bone Joint Surg Br 2004; 86: 788-92.

  3. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.

  4. National Institute for Health and Clinical Excellence: Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guideline 46: 1-160. Available at: http://www.nice.org.uk/CG046. 31-03- 2008.

  5. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW: Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 381S-453S.

  6. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J: Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407-10.

  7. Turpie AG, Bauer KA, Eriksson BI, Lassen MR: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.

  8. Colwell CW, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME: Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999; 81: 932-40.

  9. Pellegrini VD, Donaldson CT, Farber DC, Lehman EB, Evarts CM: Prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop 2005; 441: 56-62.

  10. Pellegrini VD, Clement D, Lush-Ehmann C, Keller GS, Evarts CM: Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop 1996; 333: 27-40.

  11. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W: Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-31.

  12. Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D: SACRE Study Investigators: Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162: 2191-6.

  13. Erikson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR, for the RE-NOVATE Study Group: Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.

  14. Ginsberg JS, Turkstra F, Buller HR, MacKinnon B, Magier D, Hirsh J: Posthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med 2000; 160: 669-72.

  15. Warwick D, Williams MH, Bannister GC: Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg 1995; 77: 6-10.

  16. Buehler KO, D’Lima DD, Petersilge WJ, Colwell CW Jr, Walker RH: Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty. Clin Orthop 1999; 361: 123-30.

  17. Lotke PA, Steinberg ME, Ecker ML: Significance of deep venous thrombosis in the lower extremity after total joint arthroplasty. Clin Orthop 1994; 299: 25-30.

  18. Howie C, Hughes H, Watts AC: Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005; 87: 1675-80.

  19. Seagroatt V, Tan HS, Goldacre M. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991; 303: 1431-5.

  20. Pellegrini VD, Donaldson CT, Farber DC, Lehman EB, Evarts CM. The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop 2006; 452: 21-7.

  21. Sikorski JM, Hampson WG, Staddon GE: The natural history and etiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg 1981; 63: 171-7.

  22. White RH, Henderson MC: Risk factors for venous thromboembolism after total hipand knee replacement surgery Curr Op Pulm Med 2002; 8: 365-71.

  23. Clarke MT, Green JS, Harper WM, Gregg PJ: Cement as a risk factor for deep-vein thrombosis. Comparison of cemented TKR, uncemented TKR and cemented THR. J Bone Joint Surg 1998; 80: 611-3.

  24. Samama CM, Clergue F, Barre J, Montefiore A, I ll P, Samii K: Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Br J Anaesth 1997; 78: 660-5.

  25. Lindahl TL, Lundahl TH, Nilsson L, Andersson CA: APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee: a prospective study. Thromb Haemost 1999; 81: 18-21.

  26. Salvati EA, Pellegrini VD Jr, Sharrock NE, Lotke PA, Murray DW, Potter H, Westrich GH: Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg 2000; 82: 252-70.

  27. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J: Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. J Bone Joint Surg Am 1998; 80: 1158-66.




2020     |     www.medigraphic.com